BR112015009042A8 - Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa - Google Patents

Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa

Info

Publication number
BR112015009042A8
BR112015009042A8 BR112015009042A BR112015009042A BR112015009042A8 BR 112015009042 A8 BR112015009042 A8 BR 112015009042A8 BR 112015009042 A BR112015009042 A BR 112015009042A BR 112015009042 A BR112015009042 A BR 112015009042A BR 112015009042 A8 BR112015009042 A8 BR 112015009042A8
Authority
BR
Brazil
Prior art keywords
kidney cell
trigging
implantation
identify
cell population
Prior art date
Application number
BR112015009042A
Other languages
English (en)
Other versions
BR112015009042B1 (pt
BR112015009042A2 (pt
Inventor
Basu Joydeep
Guthrie Kelly
JUSTEWICZ Dominic
Burnette Teresa
Bruce Andrew
W Kelley Russell
W Ludlow John
Original Assignee
Regenmedtx Llc
Regenmed Cayman Ltd
Inregen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenmedtx Llc, Regenmed Cayman Ltd, Inregen filed Critical Regenmedtx Llc
Publication of BR112015009042A2 publication Critical patent/BR112015009042A2/pt
Publication of BR112015009042A8 publication Critical patent/BR112015009042A8/pt
Publication of BR112015009042B1 publication Critical patent/BR112015009042B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODO PARA IDENTIFICAR UMA POPULAÇÃO DE CÉLULA RENAL HETEROGÊNEA ADEQUADA PARA IMPLANTAÇÃO E/OU DESENCADEAMENTO DE UMA RESPOSTA REGENERATIVA. A presente invenção envolve populações de célula renal de mamífero heterogêneas enriquecidas caracterizadas por biomarcadores e métodos de fazer e usar as mesmas.
BR112015009042-7A 2012-10-24 2013-10-24 Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa BR112015009042B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718150P 2012-10-24 2012-10-24
US61/718,150 2012-10-24
US201361876616P 2013-09-11 2013-09-11
US61/876,616 2013-09-11
PCT/US2013/066707 WO2014066699A1 (en) 2012-10-24 2013-10-24 Renal cell populations and uses thereof

Publications (3)

Publication Number Publication Date
BR112015009042A2 BR112015009042A2 (pt) 2017-07-04
BR112015009042A8 true BR112015009042A8 (pt) 2017-10-10
BR112015009042B1 BR112015009042B1 (pt) 2021-10-19

Family

ID=49517782

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015009042-7A BR112015009042B1 (pt) 2012-10-24 2013-10-24 Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
BR122020018576-7A BR122020018576B1 (pt) 2012-10-24 2013-10-24 Método de preparação de uma composição terapêutica adequada para gerar uma resposta regenerativa em um rim de um indivíduo, composição terapêutica e uso da mesma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020018576-7A BR122020018576B1 (pt) 2012-10-24 2013-10-24 Método de preparação de uma composição terapêutica adequada para gerar uma resposta regenerativa em um rim de um indivíduo, composição terapêutica e uso da mesma

Country Status (18)

Country Link
US (4) US20150246073A1 (pt)
EP (3) EP3567099B1 (pt)
JP (2) JP6509119B2 (pt)
KR (4) KR102215476B1 (pt)
CN (3) CN117660296A (pt)
AU (3) AU2013334276B2 (pt)
BR (2) BR112015009042B1 (pt)
CA (1) CA2889270A1 (pt)
DK (2) DK3567099T3 (pt)
ES (2) ES2876177T3 (pt)
HK (1) HK1215448A1 (pt)
HU (2) HUE054882T2 (pt)
NZ (2) NZ707873A (pt)
PL (2) PL3567099T3 (pt)
PT (1) PT2912165T (pt)
RU (1) RU2702721C2 (pt)
SI (1) SI2912165T1 (pt)
WO (1) WO2014066699A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102215476B1 (ko) 2012-10-24 2021-02-17 인리젠 신장 세포 모집단 및 이의 용도
US11123372B2 (en) * 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
BR122019015270B1 (pt) * 2016-07-29 2022-03-03 Timothy A. Bertram Uso de uma composição compreendendo uma população de células renais selecionadas para o tratamento de nefropatia diabética
CA3057498A1 (en) * 2017-03-31 2018-10-04 Deepak Jain Injectable cell and scaffold compositions
MX2019014578A (es) * 2017-06-21 2020-12-01 Timothy A Bertram Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
JP7061766B2 (ja) * 2017-09-20 2022-05-02 学校法人同志社 Ｄｊ－１タンパク質産生促進用組成物
CN109266616A (zh) * 2018-08-21 2019-01-25 山西省人民医院 一种稳定表达aqp2蛋白的人源化小鼠足细胞模型及其构建方法和应用
BR112021002703A2 (pt) * 2018-08-31 2021-05-11 Timothy A. Bertram composições compreendendo vesículas derivadas de células e usos das mesmas
AU2020266168A1 (en) * 2019-05-02 2021-12-02 Prokidney Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies
IL295156A (en) * 2020-01-28 2022-09-01 Kidneycure Ltd Process for production of kidney cells and treatment
CN116240161B (zh) * 2023-02-27 2024-05-10 四川大学华西医院 具有肾脏损伤修复作用的细胞外囊泡制备方法及应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
PT814778E (pt) 1995-03-10 2001-11-30 Roche Diagnostics Gmbh Formas de administracao farmaceuticas contendo polipeptidos sob a forma de microparticulas e processo para a sua preparacao
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
JP4057781B2 (ja) 1997-10-31 2008-03-05 チルドレンズ メディカル センター コーポレーション 膀胱再構成
CA2325983C (en) 1998-04-20 2009-02-17 Genzyme Corporation Drug delivery of proteins from polymeric blends
DE19933582A1 (de) 1999-07-17 2001-01-18 Gerhard Rosenberger Vorrichtung zum Aufnehmen von Werkstücken und/oder Werkzeugen
US6991652B2 (en) 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US7197470B1 (en) 2000-10-11 2007-03-27 Buzzmetrics, Ltd. System and method for collection analysis of electronic discussion methods
JP2004531713A (ja) 2001-04-03 2004-10-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 腎細胞癌の腫瘍マーカー
JP2005523888A (ja) 2002-01-03 2005-08-11 ザ スクリプス リサーチ インスティテュート 癌関連エピトープ
WO2003080038A1 (fr) 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Agent prophylactique ou therapeutique contre des maladies renales
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
US20040139072A1 (en) 2003-01-13 2004-07-15 Broder Andrei Z. System and method for locating similar records in a database
US20050241012A1 (en) * 2003-10-17 2005-10-27 Nigam Sanjay K Multigene profiling in the kidney to tailor drug therapy
US20050108384A1 (en) 2003-10-23 2005-05-19 Lambert John R. Analysis of message sequences
US7788087B2 (en) 2005-03-01 2010-08-31 Microsoft Corporation System for processing sentiment-bearing text
US20080161231A1 (en) * 2005-03-18 2008-07-03 Kintan Pty. Ltd. Methods and compositions for promoting organ development
US20090304639A1 (en) * 2005-04-28 2009-12-10 Takashi Yokoo Method for preparing an organ for transplantation
CA2641733C (en) 2006-02-10 2015-03-31 Tengion, Inc. Scaffolds for organ reconstruction and augmentation
US20070214097A1 (en) 2006-02-28 2007-09-13 Todd Parsons Social analytics system and method for analyzing conversations in social media
DK2078073T3 (da) 2006-10-12 2013-10-28 Ethicon Inc Nyreafledte celler og fremgangsmåder til anvendelse deraf til vævsreparation og -regenerering
US8048636B2 (en) * 2007-03-05 2011-11-01 Northshore University Healthsystem Methods of screening for modulators of h2-calponin activity
CA2688265C (en) 2007-06-08 2021-02-16 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
RU2373942C2 (ru) * 2007-12-26 2009-11-27 Федеральное государственное учреждение "Научный Центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения хронической и острой почечной недостаточности с помощью фетальных стволовых и прогениторных клеток
CA2713909C (en) 2008-02-01 2023-12-12 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8337485B2 (en) 2008-11-04 2012-12-25 Tengion, Inc. Cell-scaffold constructs
EP2186883A1 (en) * 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
EP3388509A1 (en) 2008-11-12 2018-10-17 inRegen Isolated renal cells and uses thereof
CA2770259A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting obstructive uropathy and associated disorders
CA2780320A1 (en) * 2009-11-12 2011-05-19 Tengion, Inc. Rational design of regenerative medicine products
EP2531853B1 (en) 2010-02-04 2015-06-10 Agency For Science, Technology And Research Use of novel markers of pluripotent stem cells
NZ603376A (en) 2010-05-03 2014-10-31 Tengion Inc Smooth muscle cell constructs
TWI542690B (zh) 2010-05-12 2016-07-21 再生醫學Ｔｘ有限責任公司 生物活性腎細胞
WO2011156642A1 (en) 2010-06-11 2011-12-15 Tengion, Inc. Erythropoietin-expressing adipose cell populations
CA3065694A1 (en) 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
BR112014007676A2 (pt) * 2011-09-30 2017-04-18 The Univ Of Miami células-tronco renais isoladas do rim
EP2773955B1 (en) 2011-11-04 2018-07-18 inRegen Drug screening and potency assays
WO2014066698A1 (en) 2012-10-24 2014-05-01 Metavana, Inc. Method and system for social media burst classifications
KR102215476B1 (ko) 2012-10-24 2021-02-17 인리젠 신장 세포 모집단 및 이의 용도
PT2994528T (pt) 2013-05-08 2024-02-13 Prokidney Organoides compreendendo células renais isoladas e utilizações dos mesmos
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
MX2019014578A (es) * 2017-06-21 2020-12-01 Timothy A Bertram Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
KR20230147033A (ko) * 2020-11-13 2023-10-20 티모시 에이. 버트람 풍부화된 생체활성 신장 세포 집단, 그의 특징 및 용도

Also Published As

Publication number Publication date
BR122020018576B1 (pt) 2022-07-05
ES2744979T8 (es) 2020-04-28
CN104937095B (zh) 2019-06-07
JP2019141067A (ja) 2019-08-29
EP3901251A1 (en) 2021-10-27
KR102160725B1 (ko) 2020-09-29
KR20210018965A (ko) 2021-02-18
AU2013334276A1 (en) 2015-05-14
JP2016504017A (ja) 2016-02-12
HUE046176T2 (hu) 2020-02-28
PL2912165T3 (pl) 2020-01-31
JP6509119B2 (ja) 2019-05-08
EP3567099A1 (en) 2019-11-13
US20220347221A1 (en) 2022-11-03
EP2912165B1 (en) 2019-06-19
PT2912165T (pt) 2019-09-26
AU2019204178A1 (en) 2019-07-04
AU2022201010A1 (en) 2022-03-03
DK3567099T3 (da) 2021-06-07
US20150246073A1 (en) 2015-09-03
US20200101112A1 (en) 2020-04-02
DK2912165T3 (da) 2019-09-16
KR102460536B1 (ko) 2022-10-31
PL3567099T3 (pl) 2021-11-29
RU2702721C2 (ru) 2019-10-09
ES2744979T3 (es) 2020-02-27
BR112015009042B1 (pt) 2021-10-19
KR20150085818A (ko) 2015-07-24
HK1215448A1 (zh) 2016-08-26
RU2015119514A (ru) 2016-12-20
KR20220150419A (ko) 2022-11-10
EP3567099B1 (en) 2021-04-21
HUE054882T2 (hu) 2021-10-28
SI2912165T1 (sl) 2019-11-29
EP2912165A1 (en) 2015-09-02
BR112015009042A2 (pt) 2017-07-04
KR102215476B1 (ko) 2021-02-17
KR20200113287A (ko) 2020-10-06
JP6696023B2 (ja) 2020-05-20
AU2019204178B2 (en) 2021-11-18
US20170281684A1 (en) 2017-10-05
US10363274B2 (en) 2019-07-30
WO2014066699A1 (en) 2014-05-01
US11369639B2 (en) 2022-06-28
AU2013334276B2 (en) 2019-07-04
ES2876177T3 (es) 2021-11-12
RU2019118791A (ru) 2019-07-11
NZ707873A (en) 2019-01-25
CA2889270A1 (en) 2014-05-01
CN110184232B (zh) 2023-10-20
CN110184232A (zh) 2019-08-30
CN117660296A (zh) 2024-03-08
CN104937095A (zh) 2015-09-23
NZ741724A (en) 2020-02-28

Similar Documents

Publication Publication Date Title
BR112015009042A8 (pt) Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
CL2016001190A1 (es) Cultivo de células de mamífero.
UY34697A (es) Métodos para preparar análogos de nucleótidos
EA201391245A1 (ru) Интеррогативные клеточные анализы и их применение
EA201400709A1 (ru) Молекула биспецифического антитела
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
UY34346A (es) Proteínas de fusión para tratar trastornos metabólicos
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
UY34765A (es) Compuestos novedosos.
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
UY34817A (es) Tienopirimidinas
UY34824A (es) Nucleósidos de espirooxetano de uracilo
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112014028123A2 (pt) extração de ácidos nucleicos
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
EA201490533A1 (ru) Способы и композиции для определения статуса в отношении курения
UY34317A (es) Anticuerpo antireceptor de célula T (alfa)/ß
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
BR112013019520A2 (pt) método para produção de 2,3-butanodiol por fermentação
RS54073B1 (en) STROMAL MATERIAL CELLS
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
HUP1200239A2 (en) Quantitative biomarkers of the erythrocyte membrane
UY34329A (es) Compuestos de triazolopiridina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INREGEN (KY)

B25D Requested change of name of applicant approved

Owner name: INREGEN (KY)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2013, OBSERVADAS AS CONDICOES LEGAIS.